Showing 1201-1210 of 3001 results for "".
- “Giants of MS” Award Presented to 7 MS Leaders at 2024 CMSC Annual Meetinghttps://practicalneurology.com/news/giants-of-ms-award-presented-to-7-ms-leaders-at-2024-cmsc-annual-meeting/2470488/Several leaders in different areas of multiple sclerosis (MS) research received the “Giants of MS” award for their contributions and achievements. One recipient was selected for each of the 7 award categories, including: Advanced Care Provider, Mental Health, Neurology, Nursing, Pharm
- Relapse Patterns in MS Patients During Pregnancy and Postpartumhttps://practicalneurology.com/news/relapse-patterns-in-ms-patients-during-pregnancy-and-postpartum/2470132/A retrospective, observational study of relapse patterns in women with MS who took disease-modifying therapies (DMT) either before o
- Comorbidities Linked with Increased Disease Activity in Individuals with MShttps://practicalneurology.com/news/comorbidities-linked-with-increased-disease-activity-in-individuals-with-ms/2470579/Study results presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) demonstrated that higher comorbidity burden is associated with increased disease activity in people with multiple sclerosis (MS). This study emphasizes the importance
- Novel Proteomics Study Shows New Evidence of Association between NfL and MS Progression along with 11 CSF Proteins Associated with Long-Term MS Disabilityhttps://practicalneurology.com/news/novel-proteomics-study-shows-new-evidence-of-association-between-nfl-and-ms-progression-along-with-11-csf-proteins-associated-with-long-term-ms-disability/2470334/Analysis from a proteomics study published in Nature Communications revealed that neurofilament light chain (NfL) was the most powerful predictor of multiple sclerosis (MS) activity and a combination of 11 cerebrospinal fluid (CSF) proteins was useful in predicting long-term MS disabilit
- Fewer Serious Infections Found in MS Patients Treated with Natalizumab Vs Ocrelizumabhttps://practicalneurology.com/news/fewer-serious-infections-found-in-ms-patients-treated-with-natalizumab-vs-ocrelizumab/2470129/A study based on a large insurance claims database found that individuals diagnosed with multiple sclerosis (MS) treated with natali
- Smoking Cessation Helps Improve Outcomes for Black People Living with MShttps://practicalneurology.com/news/smoking-cessation-helps-improve-outcomes-for-black-people-living-with-ms/2470581/Tobacco smoking cessation may improve clinical outcomes for Black people with multiple sclerosis (MS), according to study results presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Compared with Non-Hispanic White people with MS, B
- Large Scale Survey of Patients with MS Uncovers Significant Barriers to Care: 42% of Respondents Do Not See an MS Specialisthttps://practicalneurology.com/news/large-scale-survey-of-ms-patient-needs-uncovers-significant-barriers-to-care-42-do-not-see-an-ms-specialist/2470481/Results from a large-scale, national survey highlight the significant barriers that people living with multiple sclerosis (MS) face in accessing resources and health care in the United States. The top barriers identified from the survey commissioned by The Multiple Sclerosis Association of Americ
- Study Examines Effects of Chemotherapy in Individuals with Cancer and MShttps://practicalneurology.com/news/study-examines-effects-of-chemotherapy-in-individuals-with-cancer-and-ms/2483538/New findings from an analysis of data from the MSBase registry (MSBase.org) suggest that chemotherapy for cancer may be associated with a temporary protective effect against multiple sclerosis (MS) relapses, offering clinicians important real-world insights on disease-modifying therapy (DMT) mana
- Anaphylaxis Boxed Warning Added to MS Medication Labelhttps://practicalneurology.com/news/anaphylaxis-boxed-warning-added-to-ms-medication-label/2473770/The Food and Drug Administration (FDA) has added a Boxed Warning to the prescribing information of glatiramer acetate, a medication for multiple sclerosis (MS) sold under the brand name Copaxone (glatiramer acetate injection; Teva, Tel Aviv-Yafo, Israel) and the generic name Glatopa (glatiramer a
- McDonald Criteria Updates for MS Diagnosis Announcedhttps://practicalneurology.com/news/mcdonald-criteria-updates-for-ms-diagnosis-announced/2470587/Proposed revisions to the 2017 McDonald diagnostic criteria for multiple sclerosis (MS) were announced at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The updates, which will be published later this year, provide guidance on the use of im